Circadian Technologies Limited Stock Australian S.E.
Equities
AU000000CIR6
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- AUD | - |
May. 28 | Opthea Limited Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD | CI |
May. 28 | Opthea Completes Enrollments in COAST, ShORe Trials | MT |
Sales 2024 * | 908K 599K | Sales 2025 * | 17.43M 11.49M | Capitalization | 321M 212M |
---|---|---|---|---|---|
Net income 2024 * | -276M -182M | Net income 2025 * | -223M -147M | EV / Sales 2024 * | 521 x |
Net Debt 2024 * | 151M 99.89M | Net Debt 2025 * | 209M 138M | EV / Sales 2025 * | 30.4 x |
P/E ratio 2024 * |
-1.06
x | P/E ratio 2025 * |
-1.51
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.31% |
Managers | Title | Age | Since |
---|---|---|---|
Frédéric Guerard
CEO | Chief Executive Officer | 51 | 23-10-26 |
Megan Baldwin
FOU | Founder | 49 | 07-12-31 |
Peter F. Lang
DFI | Director of Finance/CFO | 52 | 23-10-26 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jeremy Levin
CHM | Chairman | 70 | 20-10-04 |
Quinton Oswald
BRD | Director/Board Member | - | 22-04-20 |
Lawrence Gozlan
BRD | Director/Board Member | 45 | 20-07-23 |
1st Jan change | Capi. | |
---|---|---|
+51.85% | 57.87B | |
+41.00% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |